Not independent
Tenure on this board
0.5 yrs
Also a director at
Lineage Cell Therapeutics Inc (LCTX)
Meeting calendar
STAA · Special meeting · Thursday, October 23, 2025Contested
Staar Surgical Co
5 nominees · 2 ballot items · contested.
Two Broadwood-proposed shareholder proposals to oppose the proposed Alcon merger: Proposal 1 to approve the Merger Agreement; Proposal 2 to approve non-binding compensation for named executives in connection with the merger.
Market cap
$1.4B
1Y TSR
+70.4%
Board grade
C
Record date
Sep 12, 2025
Filing
DEFC14A
Meeting concluded · Oct 23, 2025
Follow how the vote landed and what changed on Staar Surgical Co’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
MERGER AGREEMENT PROPOSAL
Shareholder — Broadwood Partners, L.P.Ask stockholders to approve the Merger Agreement and related merger transactions with Alcon; Broadwood opposes the merger and urges a vote against.
- 2
COMPENSATION PROPOSAL
ShareholderYou are being asked by the Company to approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company’s named executive officers in connection with the Merger Agreement and the transactions contemplated thereby. For the reasons discussed in the above section titled “Reasons to Vote Against the Merger Agreement Proposal”, we OPPOSE the Proposed Merger. To that end, we are soliciting your proxy to vote “AGAINST” the Compensation Proposal so that there can be no doubt that the Company’s stockholders oppose the Proposed Merger.
Director elections
Nominees on the ballot5
Not independent
Tenure on this board
0.5 yrs
Natalie R. Capasso
Not independent
Tenure on this board
New nominee
Raymond A. Myers
Not independent
Tenure on this board
New nominee
Jason J. Martin
Not independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | BROADWOOD CAPITAL INC | 32.4% | 16,123,842 | $302M |
| 2 | BlackRock, Inc. | 9.5% | 4,748,575 | $89M |
| 3 | Yunqi Capital Ltd | 6.5% | 3,257,130 | $61M |
| 4 | Madison Avenue Partners, LP | 4.9% | 2,441,678 | $46M |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 2,123,589 | $40M |
| 6 | STATE STREET CORP | 3.7% | 1,832,996 | $34M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 1,690,606 | $32M |
| 8 | Anatole Investment Management Ltd | 3.2% | 1,601,701 | $30M |
| 9 | BlackRock, Inc. | 2.6% | 1,290,349 | $24M |
| 10 | Two Seas Capital LP | 2.1% | 1,036,973 | $19M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Staar Surgical Co’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.9B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$2.0B
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Reference
Frequently asked questions
- When is the Staar Surgical Co 2025 special meeting?
- Staar Surgical Co (STAA) holds its 2025 special shareholder meeting on Thursday, October 23, 2025.
- What is the record date for the Staar Surgical Co 2025 meeting?
- The record date for the Staar Surgical Co 2025 meeting is Friday, September 12, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Staar Surgical Co's 2025 meeting?
- The board is presenting 5 director nominees at the Staar Surgical Co 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Staar Surgical Co 2025 meeting?
- Shareholders will vote on 2 proposals at the Staar Surgical Co 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.